Two-year lung cancer survival between 2000 to 2020: Results from 3 French nationwide cohorts.

person Didier Debieuvre Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France info_outline Didier Debieuvre, Isabelle Monnet, Olivier Bylicki, Sophie Schneider, Francois Goupil, Benoit Godbert, Christine Dussopt, Herve Pegliasco, Laurent Portel, Reda Chikouche, Philippe Masson, Mohamad Jaafar, Clothilde Marty, Fethi EL Khanjari, Julie Obert, Marjorie Picaud, Anne Sophie Bravard, Herve Le Floch, Alexia Letierce, Hugues Morel

Authors person Didier Debieuvre Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France info_outline Didier Debieuvre, Isabelle Monnet, Olivier Bylicki, Sophie Schneider, Francois Goupil, Benoit Godbert, Christine Dussopt, Herve Pegliasco, Laurent Portel, Reda Chikouche, Philippe Masson, Mohamad Jaafar, Clothilde Marty, Fethi EL Khanjari, Julie Obert, Marjorie Picaud, Anne Sophie Bravard, Herve Le Floch, Alexia Letierce, Hugues Morel Organizations Service de Pneumologie, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, hôpital Émile-Muller, Mulhouse, France, CHI De Creteil, Créteil, France, HIA SAINTE ANNE, Toulon, France, Hospital Center De La Cote Basque, Bayonne, France, Centre Hospitalier, Le Mans, France, Hôpital Robert Schuman, Service de Pneumologie, Metz, France, Hopital Nord Ouest (HNO), Villefranche-Sur-Saône, France, Hôpital Européen Marseille, Marseille, France, Centre Hospitalier Robert Boulin, Libourne, France, Centre Hospitalier Auxerre, Auxerre, France, Cholet Hospital Centre, Cholet, France, Centre Hospitalier Eure-Seine-Evreux, Evreux, France, Centre Hospitalier Saint Nazaire, Saint-Nazaire, France, Centre Hospitalier Blois, Blois, France, Centre Hospitalier le Raincy Montfermeil, Montfermeil, France, Centre Hospitalier Tourcoing, Tourcoing, France, CH Avranches, Avranches, France, Hôpital d'instruction des armées Percy, Clamart, France, Qualitystat, Morangis, France, Service Pneumologie Oncologie Thoracique, Orléans, France Abstract Disclosures Research Funding Pharmaceutical/Biotech Company AstraZeneca, BMS, MSD, Janssen, Bayer, Boehringer Ingelhei, Lilly, Takeda, Sanofi, Roche, Chugai, Pfizer, Fondation du Souffle, Le Nouveau Souffle, Couleur Espoir, the labeling of InCa and FHF-CNCR Background: Each decade since 2000, the French College of General Hospital Pulmonologists (CPHG) conducts the KBP study, a real-life nationwide prospective multicenter study on LC in non-academic public hospital (NPH). Here, we report the two-year survival (2-y) rate among the 2020 cohort and the comparisons with the 2000 and 2010 cohorts. Methods: Collection of all consecutive diagnosed LC, all stage and all histology, between 01/01 and 12/31 in NPH pulmonology or oncology units in 2000, 2010 and 2020 with the same methodology. A Scientific Committee controlled inclusion exhaustivity and quality in each center. Survival rates were calculated using the Kaplan-Meier method and risk factors were assessed using Cox models. Results: 8,999 patients were included in 82 centers in 2020. The 2-y survival rate was 40.3%, the median overall survival was 15.3 months. Compared to 2000, mortality rates at 2 years decreased significantly (-19.1%), while early (1 month and 3 months) mortality remains similar. Survival improved in 20 years whatever histologic types (Table). Factors associated with 2-y survival were sex (36.1% vs 48.1% respectively for male and female respectively, significantly increased over 20 years: + 15.3% for M and + 24.5% for F), high age (>80 y-o), poor ECOG status (3 or 4) and advanced disease. As expected in 2020, TNM stage was still determining for 2-year mortality, 15.2 [12.6-17.7] stage I vs 75.6 [74.4-76.8] stage IV. In 2020 the Covid-19 infection (n=283) impacted the survival (HR = 4.02 95%CI [3.33-4.86]) on multivariate analysis adjusted to age, sex, tobacco consumption, histology, ECOG status, TNM stage. Conclusions: These results confirmed the major improvement in the last two decades for LC. 5-years survival will provide us more enlightenment. Mortality rates* - % [95% IC]. Overall mortality Months 2000 2010 2020 1 10.4 [9.6 - 11.2] 9.8 [9.1 - 10.4] 8.2 [7.7 - 8.8] 3 24.6 [23.4 - 25.7] 23.3 [22.3 - 24.3] 20.2 [19.4 - 21.0] 12 60.1 [58.8 - 61.4] 56.9 [55.7 - 58.0] 44.5 [43.4 - 45.5] 24 78.8 [77.7 - 79.8] 74.2 [73.2 - 75.3] 59.7 [58.7 - 60.8] Median survival time (months) 8.8 [8.4 - 9.1] 9.7 [9.4 - 10.1] 15.3 [14.6-16.1] Mortality / histology Months 2000 2010 2020 SCLC 24 88.3 [86.0 - 90.3] 86.4 [84.0 - 88.4] 80.6 [78.0 - 82.9] Squamous 24 75.6 [73.7 - 77.4] 70.9 [68.8 - 73.0] 61.5 [59.1 - 63.6] Non-SCLC, non-squamous 24 76.5 [74.3 - 78.5] 72.3 [70.7 - 73.9] 54.4 [52.9 - 55.9] *Preliminary results with 1291 missing data at Month 24 – Update will be available for the congress.